

CLAIMS

1. Use of an antisense oligonucleotide in the manufacture of a medicament for treating and/or delaying progression of glaucoma in a subject, wherein the antisense oligonucleotide increases the level of *OPA1* mRNA or the amount of functional *OPA1* protein in a cell and/or a tissue of the subject.
2. The use of claim 1, wherein:
 - (i) the amount of functional *OPA1* protein in the cell and/or the tissue is increased by about 1.1 to about 10-fold; and/or
 - (ii) the tissue is selected from the group consisting of the retina, retinal pigment epithelium and combinations thereof.
3. The use of claim 1 or claim 2, wherein the antisense oligonucleotide binds to a targeted portion of the 5' untranslated region (UTR) of an *OPA1* gene transcript in a cell to increase translation efficiency of an *OPA1* mRNA and/or to increase transcript stability of an *OPA1* mRNA, wherein the targeted portion is within the nucleotide sequence corresponding to **SEQ ID NO: 55**.
4. The use of any one of claims 1 to 3, wherein the antisense oligonucleotide comprises a backbone modification.
5. The use of any one of claims 1 to 4, wherein the antisense oligonucleotide comprises:
 - (i) a backbone modification comprising a phosphorothioate linkage or a phosphorodiamidate linkage; and/or
 - (ii) a phosphorodiamidate morpholino, a locked nucleic acid, a peptide nucleic acid, a 2'-*O*-methyl, a 2' -Fluoro, or a 2'-*O*-methoxyethyl moiety; and/or
 - (iii) at least one modified sugar moiety; and/or
 - (iv) a 2'-*O*-methoxyethyl moiety.
6. The use of any one of claims 1 to 5, wherein:
 - (i) each sugar moiety in the antisense oligonucleotide is a modified sugar moiety; and/or
 - (ii) each nucleotide of the antisense oligonucleotide comprises a 2'-*O*-methoxyethyl moiety.

7. The use of any one of claims 1 to 6, wherein the nucleotide sequence of the antisense oligonucleotide consists of 10 to 50 nucleotides, 15 to 40 nucleotides, 18 to 40 nucleotides, 17 to 25 nucleotides, 20 to 35 nucleotides, 20 to 30 nucleotides, 22 to 30 nucleotides, 22 to 28 nucleotides, 24 to 30 nucleotides, 25 to 30 nucleotides, or 26 to 30 nucleotides; or wherein the nucleotide sequence of the antisense oligonucleotide consists of 20 to 30 nucleotides.
8. The use of any one of claims 1 to 7, wherein the antisense oligonucleotide comprises one or more phosphorodiamidate morpholino moieties.
9. The use of any one of claims 1 to 8, wherein the antisense oligonucleotide is linked to a functional moiety, wherein the functional moiety:
- (i) comprises or consists of a delivery moiety or a stabilising moiety; and/or
 - (ii) is covalently or non-covalently linked to the antisense oligonucleotide; and/or
 - (iii) is linked to the 5' end of the antisense oligonucleotide or is linked to the 3' end of the antisense oligonucleotide.
10. The use of claim 9, wherein the delivery moiety:
- (i) is selected from the group consisting of lipids, peptides, carbohydrates, and antibodies; and/or
 - (ii) comprises a cell-penetrating peptide (CPP) or a N-acetylgalactosamine (GalNAc) moiety.
11. The use of any one of claims 1 to 10, wherein the nucleotide sequence of the antisense oligonucleotide:
- (i) is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% complementary to the nucleotide sequence of the targeted portion over the length of the antisense oligonucleotide; and/or
 - (ii) corresponds to any one of **SEQ ID NOs: 112, 60, 77, 78, 80, 109, 110 or 113**.
12. The use of any one of claims 1 to 10, wherein the nucleotide sequence of the antisense oligonucleotide corresponds to **SEQ ID NO: 112**.
13. The use of any one of claims 1 to 12, wherein the antisense oligonucleotide is complexed with a delivery nanocarrier.

14. The use of any one of claims 1 to 13, wherein the antisense oligonucleotide is formulated for a route of administration selected from the group consisting of intravitreal, suprachoroidal, subretinal, ciliary intramuscular, intravenous, intra-arterial, subcutaneous, and topical routes.